Wang Jin-Sheng, Shen Yi-Gen, Yin Ri-Peng, Thapa Saroj, Peng Yang-Pei, Ji Kang-Ting, Liao Lian-Ming, Lin Jia-Feng, Xue Yang-Jing
Department of Cardiology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Xueyuanxi Road, No 109, Wenzhou, 325000, Zhejiang, China.
Department of Laboratory Medicine, Union Hospital, Fujian Medical University, Fuzhou, 350122, Fujian, China.
BMC Cardiovasc Disord. 2018 Aug 31;18(1):177. doi: 10.1186/s12872-018-0913-2.
Patients with frequent premature ventricular contractions (PVCs) are often symptomatic. Catheter ablation was usually indicated to eliminate symptoms in patients with PVCs-induced cardiomyopathy. Currently, PVCs-ablation is also applied for patients with PVCs and no structural heart diseases (SHD); however, the safety and efficacy of ablation in these patients remains unclear.
In this retrospective study, data from patients who underwent ablation for PVCs from January 2010 to December 2016 at our hospital was retrieved. Predictors of complications and acute procedural success were evaluated.
A total of 1231 patients (mean age 47.8 ± 16.8 years, 59% female) were included. The overall complication rate was 2.7%, and the most common complication was hydropericardium. Two ablation-related mortalities occurred. One patient died of coronary artery injury during the procedure and the other died from infectious endocarditis. Location (left ventricle and epicardium) was the main predictor of complications, with right ventricular outflow tract (RVOT) predicting fewer complications. The acute procedural success rate was 94.1% in all patients. The main predictor of acute procedural success was RVOT origin, while an epicardial origin was a predictor of procedural failure.
Locations of left ventricle and epicardium were predictors of procedural complications for patients with PVCs. Therefore, ablation is not recommended in these patients. For other origins of PVCs, particularly RVOT origin, ablation is a safety and effective treatment.
频发室性早搏(PVC)患者常伴有症状。导管消融通常用于消除PVC诱发的心肌病患者的症状。目前,PVC消融也应用于无结构性心脏病(SHD)的PVC患者;然而,这些患者消融的安全性和有效性仍不明确。
在这项回顾性研究中,检索了2010年1月至2016年12月在我院接受PVC消融治疗患者的数据。评估并发症和急性手术成功率的预测因素。
共纳入1231例患者(平均年龄47.8±16.8岁,59%为女性)。总体并发症发生率为2.7%,最常见的并发症是心包积液。发生了两例与消融相关的死亡。1例患者在手术过程中死于冠状动脉损伤,另1例死于感染性心内膜炎。部位(左心室和心外膜)是并发症的主要预测因素,右心室流出道(RVOT)并发症较少。所有患者的急性手术成功率为94.1%。急性手术成功的主要预测因素是RVOT起源,而心外膜起源是手术失败的预测因素。
左心室和心外膜部位是PVC患者手术并发症的预测因素。因此,不建议对这些患者进行消融。对于其他起源的PVC,特别是RVOT起源,消融是一种安全有效的治疗方法。